RBC Capital Upgrades Proteostasis Therapeutics (PTI) to Outperform Following 'Impressive Ph.II CF Doublet Data'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams upgraded Proteostasis Therapeutics (NASDAQ: PTI) from Sector Perform to Outperform with a price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
